Here's what we'll cover
Here's what we'll cover
If you're taking Wegovy or considering it, you may have seen alarming headlines about a rare "eye stroke" linked to the drug. Before panic sets in, it helps to understand what the research actually shows, how rare this condition is, and what it means for your personal decision-making.
What Is NAION, the "Eye Stroke"?
Non-arteritic anterior ischemic optic neuropathy, or NAION, is a condition where blood flow to the optic nerve is suddenly reduced or cut off. The optic nerve is the cable that transmits visual information from your eye to your brain. When it loses adequate blood supply, the nerve tissue can be damaged permanently.
The term "eye stroke" is informal but apt. Like a stroke in the brain, NAION happens suddenly, usually without warning, and the damage it causes can be irreversible.
What Does NAION Feel Like?
Most people with NAION wake up and notice blurred or lost vision in one eye. It is typically painless, which makes it especially alarming because there's no discomfort to prompt someone to seek help. Vision loss can range from a small blind spot to near-total loss of usable vision in the affected eye.
NAION is not common in the general population. Estimates suggest roughly 2 to 10 cases per 100,000 people per year in the United States. It tends to affect people over 50, and those with certain vascular risk factors are at higher baseline risk.
What the Research Shows About Wegovy and NAION
The connection between semaglutide and NAION first drew serious attention after a study published in JAMA Ophthalmology in mid-2024. Researchers at Massachusetts Eye and Ear looked at a large patient database and found that people with obesity who were prescribed semaglutide had a meaningfully higher rate of NAION compared to those prescribed other weight-loss medications.
A second analysis, focused on patients with type 2 diabetes taking semaglutide (including Ozempic), found a similar elevated signal. The association has now appeared in multiple datasets, which is why it has continued to draw scientific attention into 2025 and 2026.
Is This a Proven Cause-and-Effect Relationship?
No, not yet. These are observational studies, meaning researchers identified a statistical association. They cannot definitively prove that semaglutide directly causes NAION. It's possible that underlying health conditions common in people prescribed semaglutide, such as obesity, diabetes, or high blood pressure, are contributing to the elevated risk rather than the drug itself.
That said, the signal has been consistent enough across studies that researchers and regulators are taking it seriously. Dismissing it outright would be premature.
How High Is the Actual Risk?
Context matters enormously here. Let's look at the numbers as clearly as possible.
The JAMA Ophthalmology study found that among patients with obesity, roughly 20 out of 10,000 semaglutide users developed NAION over approximately two years. That compares to about 9 out of 10,000 in the comparison group taking other weight-loss medications. The risk was elevated, but the absolute numbers remain small.
To put this in perspective: the risk roughly doubled relative to comparison groups, but the absolute number of people affected remained quite low. Doubling a small risk still produces a small risk. However, because NAION can cause permanent vision loss, even a low absolute risk deserves serious consideration.
Who May Be at Higher Risk?
Not everyone taking semaglutide faces equal risk. Based on what researchers have identified, certain individuals may be more vulnerable to NAION.
Risk Factors to Discuss With Your Doctor
- Prior NAION in one eye, since people who have already had NAION in one eye face a significantly higher risk of developing it in the other eye, regardless of any medication
- Small optic disc anatomy, sometimes called a disc at risk, which is a structural feature some people are born with that an ophthalmologist can identify during an eye exam
- Type 2 diabetes, which affects blood vessels throughout the body including those supplying the optic nerve
- High blood pressure, which is a known independent risk factor for NAION unrelated to any medication
- Sleep apnea, since untreated obstructive sleep apnea has been associated with increased NAION risk in some research
- Being over 50, since risk increases with age in a pattern consistent with vascular disease generally
If several of these apply to you, a conversation with both your prescribing provider and an eye specialist becomes especially worthwhile before continuing or starting semaglutide.
What Has the FDA Said?
As of the time of this writing, the FDA has not issued a formal label update for Wegovy or Ozempic specifically warning about NAION. However, the agency has acknowledged the research signal and has indicated that the data is being evaluated.
This does not mean the concern is being ignored. Regulatory label changes typically take time, require careful review of multiple data sources, and must weigh benefit-risk tradeoffs carefully. The cardiovascular and metabolic benefits of semaglutide are well-documented and substantial for many patients, which complicates any straightforward risk assessment.
It's worth monitoring FDA announcements and discussing any updates with your doctor as new guidance becomes available.
Does Tirzepatide (Mounjaro, Zepbound) Carry the Same Risk?
Mounjaro and its weight-loss-approved counterpart Zepbound contain tirzepatide, a dual GIP/GLP-1 receptor agonist. Tirzepatide works through overlapping but distinct mechanisms compared to semaglutide.
At this point, the NAION research has specifically focused on semaglutide-based medications. There is not yet equivalent published evidence linking tirzepatide to NAION. However, it is too early to declare tirzepatide free of this association. The research simply hasn't caught up yet, and it would be premature to switch medications based solely on this concern without speaking to a physician.
Practical Steps If You're Currently Taking Wegovy
If you're already on Wegovy, here's how to think through this in a practical, non-panic way.
Don't stop abruptly without medical guidance. Discontinuing semaglutide suddenly can cause rapid weight regain and may interfere with blood sugar management if you have diabetes. Any medication changes should involve your provider.
Schedule a baseline eye exam if you haven't had one recently. An ophthalmologist, a medical doctor specializing in eye health, can assess your optic disc anatomy, check for early signs of vascular changes, and document your baseline vision. This is smart practice for anyone over 40, and it becomes more important if you're on a medication with any ocular signal in the research.
Know the symptoms of NAION. Sudden painless vision loss or blurring in one eye, especially upon waking, is the classic presentation. If this happens, treat it as a medical emergency. Call your eye doctor or go to an emergency room immediately. Time matters for any vascular event.
Review your other risk factors with your provider. Blood pressure control, sleep apnea treatment, and blood sugar management all intersect with NAION risk. Addressing these factors benefits your overall health regardless of medication choice.
No waiting list. No insurance needed.
Frequently Asked Questions
Can Wegovy cause blindness?
Research has found a statistical association between Wegovy (semaglutide) and a rare eye condition called NAION, which can cause permanent vision loss in one eye. The absolute risk is low, affecting roughly 20 out of 10,000 users in one key study, but the condition is serious because the damage can be irreversible. Talk to your doctor about your individual risk factors.
What is NAION and why is it called an "eye stroke"?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the optic nerve is suddenly interrupted, similar to how a stroke cuts blood flow to part of the brain. The result is sudden, painless vision loss, usually in one eye, that can be permanent.
Should I stop taking Wegovy because of the eye stroke risk?
You should not stop Wegovy abruptly without speaking to your prescribing doctor. The risk of NAION is real but low, and your provider will weigh it against the well-documented benefits of semaglutide for weight loss and cardiovascular health. A personalized conversation about your specific risk factors is the right approach.
What are the warning signs of NAION I should watch for?
The most common sign is waking up with sudden blurred or lost vision in one eye. It is usually painless. If this happens to you, treat it as a medical emergency and seek immediate care from an ophthalmologist or emergency department. Do not wait to see if it resolves on its own.
Does Mounjaro or tirzepatide carry the same eye stroke risk?
Current research on NAION has focused specifically on semaglutide-based medications like Wegovy and Ozempic. There is no published evidence yet linking tirzepatide (Mounjaro, Zepbound) to NAION, but the research is still early and tirzepatide has not been formally cleared of this concern. Speak with your doctor before switching medications based on this issue.
Has the FDA issued any warning about Wegovy and eye problems?
As of mid-2026, the FDA has not issued a formal label update for Wegovy or Ozempic specifically warning about NAION. The agency is evaluating the available data. This regulatory process takes time, especially when a drug has well-established benefits that must be weighed against an emerging risk signal.
Questions to Ask Your Doctor at Your Next Appointment
Knowing what to ask can make a routine appointment far more productive. Here are specific questions worth raising with your prescribing provider or eye doctor.
- Do I have any structural or vascular risk factors that would increase my personal NAION risk?
- Should I get a baseline eye exam with an ophthalmologist before continuing semaglutide?
- Are my blood pressure and blood sugar controlled well enough to minimize vascular risk?
- What symptoms should prompt me to call your office or go to the ER immediately?
- Is there a GLP-1 alternative that might be better suited to my risk profile?
- How does my NAION risk compare to the cardiovascular benefits I'm getting from this medication?
These questions won't alarm a good provider. They signal that you're an engaged patient making informed decisions, which is exactly what responsible medication use looks like.
The Bottom Line: Informed, Not Alarmed
The connection between Wegovy and NAION is a legitimate research signal that deserves attention. It is not a reason for widespread panic, and it is not a reason to avoid GLP-1 medications categorically. The data shows an elevated relative risk against a backdrop of low absolute risk, and the benefits of semaglutide for people with obesity or type 2 diabetes remain meaningful and well-established.
What this research does highlight is the importance of personalized medical care. GLP-1 medications are not one-size-fits-all. Your health history, your risk factors, and your treatment goals all matter when deciding whether to start, continue, or adjust your medication.
The best thing you can do right now is schedule a conversation with your provider, get a current eye exam if it's been a while, and stay informed as additional research and potential FDA guidance emerges.
If you're still evaluating your options or comparing providers, GLP-1.com's provider comparison tool can help you find a licensed clinician who will take the time to assess your individual risk profile. You can also explore GLP-1 coupons and savings options if cost is part of your decision-making. Whatever you decide, make sure it's a decision made with full information and the support of a qualified healthcare provider.